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Inhibitors of the cystic fibrosis transmembrane con-
ductance regulator (CFTR) chloride channel have
potential application as antisecretory therapy in
cholera. We synthesized mono- and divalent CFTR
inhibitors consisting of a malonic acid hydrazide
(MalH) coupled via a disulfonic stilbene linker to poly-
ethylene glycols (PEGs; 0.2–100 kDa). IC50 values for
CFTR inhibition were 10–15 mM for the monovalent
MalH-PEGs, but substantially lower for divalent
MalH-PEG-MalH compounds, decreasing from 1.5 to
0.3 mM with increasing PEG size and showing pos-
itive cooperativity. Whole-cell patch-clamp showed
voltage-dependent CFTR blockwith inward rectifica-
tion. Outside-out patch-clamp showed shortened
single-channel openings, indicating CFTRpore block
from the extracellular side. Luminally added MalH-
PEG-MalH blocked by >90% cholera toxin-induced
fluid secretion in mouse intestinal loops (IC50 10
pmol/loop), and greatly reduced mortality in a suck-
ling mouse cholera model. These conjugates may
provide safe, inexpensive antisecretory therapy.
INTRODUCTION
Secretory diarrheas, such as those produced by enterotoxins
from Vibrio cholerae (in cholera) and Escherichia coli (in traveler’s
diarrhea) involve active chloride secretion by enterocytes into the
intestinal lumen, creating a driving force for sodium and water
secretion. Evidence from cell culture and animal models (Clarke
et al., 1992; Gabriel et al., 1994; Kunzelmann and Mall, 2002;
Field, 2003; Thiagarajah et al., 2003) indicate that intestinal chlo-
ride secretion in enterotoxin-mediated secretory diarrheas oc-
curs mainly through the cystic fibrosis transmembrane conduc-
tance regulator (CFTR) protein, a chloride channel regulated
by cAMP-dependent phosphorylation, which, when mutated,
causes the hereditary disease cystic fibrosis (Boucher, 2004).
CFTR inhibition is predicted to be of clinical benefit as antisecre-
tory therapy in various types of diarrheas (Barrett and Keely,
2000; Li et al., 2005; Thiagarajah and Verkman, 2005), as well
as in retarding cyst growth in autosomal dominant polycystic
kidney disease where fluid secretion into the lumen of expanding
cysts is CFTR-dependent (Li et al., 2004; Yang et al., 2008).718 Chemistry & Biology 15, 718–728, July 21, 2008 ª2008 ElsevierHigh-throughput screening of drug-like small molecules has
yielded two classes of CFTR inhibitors with micromolar potency
(Ma et al., 2002; Muanprasat et al., 2004). The thiazolidinone
CFTRinh-172 acts from the cytoplasmic side of the plasma mem-
brane to produce a voltage-independent CFTR block in which
the channel closed state is stabilized (Ma et al., 2002; Taddei
et al., 2004). CFTRinh-172 is absorbed rapidly across the intesti-
nal wall and undergoes intestinal accumulation by an enterohe-
patic circulation mechanism (Sonawane et al., 2005). In rodent
models, systemically administered CFTRinh-172 blocked cholera
toxin- and heat stable E. coli (STa) toxin-induced intestinal fluid
secretion (Thiagarajah et al., 2003). Prior, less potent CFTR inhib-
itors, such as glibenclamide, diphenylamine-2-carboxylate, 5-ni-
tro-2(3-phenylpropyl-amino)benzoate, and flufenamic acid, also
act from the cytoplasmic side, but generally produce outwardly
rectifying currents suggestive of an internal pore occlusion
mechanism (Sheppard and Welsh, 1992; McCarty et al., 1993;
Walsh et al., 1999; Hwang and Sheppard, 1999; Zhou et al.,
2002). Recently, a-aminoazaheterocycle-methylglyoxal adducts
were reported as potent CFTR inhibitors (Routaboul et al., 2007);
however, through the use of several function CFTR assays, we
could not confirm these findings (Sonawane et al., 2008). A sec-
ond class of small-molecule CFTR inhibitors discovered in
a larger screen designed to identify inhibitors with an external
site of action, the glycine hydrazides, such as GlyH-101
(Figure 1A, left), produce inwardly rectifying chloride currents
with rapid channel flicker, suggesting external pore occlusion
(Muanprasat et al., 2004). The expression of CFTR at the lu-
men-facing plasma membrane in intestinal epithelium provides
an opportunity to develop nonabsorbable, and therefore poten-
tially very safe, antisecretory agents for diarrhea therapy.
To prove an external site of action for the glycine hydrazides,
polyethylene glycol (PEG) conjugates of related malonic acid hy-
drazide (MalH) analogs were synthesized (Figure 1A, center) and
found to block CFTR chloride current rapidly and fully when
added to solutions bathing the external cell surface (Sonawane
et al., 2006). The MalH-PEG conjugates prevented cholera
toxin-induced intestinal fluid secretion when present in the lu-
men of closed intestinal loops in mice. However, the IC50 values
for CFTR inhibition by MalH-PEG conjugates were generally >5
mM, and inhibition was reversed rapidly following washout, which
are potential concerns for oral therapy of severe secretory diar-
rhea where rapid intestinal fluid transit might reduce compound
activity by dilutional washout. We recently introduced a novel ap-
proach to address these concerns by MalH conjugation to lec-
tins; the MalH-lectins had substantially improved CFTR inhibitionLtd All rights reserved
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CFTR Inhibitors for Cholera TherapyFigure 1. Synthesis of Monovalent and Divalent MalH-PEGs
(A) Structures of the GlyH-101, MalH-(PEG)1, and the MalH moiety.
(B) Synthesis of MalH-PEGs. MalH-DIDS was conjugated to monoamino and bisamino PEGs to produce MalH-PEG and MalH-PEG-MalH conjugates. Reaction
conditions: TEA, DMSO, room temperature, 24 hr.
(C) Synthesis of bisamino PEG 40 kD and 108 kDa. From left to right: TsCl, TEA, DCM; NaN3, DMF, 40
C; PPh3, H2O.potency down to 50 nM, and resisted intestinal washout because
of their high affinity and entrapment in the enterocyte glycocalyx
(Sonawane et al., 2007). Although effective, the relatively high
cost and limited stability of protein-based therapeutics are dis-
advantages for use in developing countries. Here, based on
the emerging paradigm of enhanced potency of multivalent li-
gands (Gestwicki et al., 2002; Handl et al., 2007) and evidence
for CFTR channel clustering (Krouse and Wine, 2001), possibly
mediated by PDZ-domain interactions (Wang et al., 2000), and
evidence of dimeric/oligomeric CFTR assembly in membranes
(Zerhusen et al., 1999; Ramjeesingh et al., 2003; Schillers
et al., 2004), we evaluated the utility of divalent, macromolecular
MalH conjugates as externally acting CFTR inhibitors. Large, di-
valent MalH-PEG conjugates were found to block CFTR chloride
current with high potency and showed antidiarrheal efficacy in
mouse models of cholera.
RESULTS
Synthesis of MalH-PEG Conjugates
As mentioned in the INTRODUCTION, we postulated that diva-
lent compounds consisting of two CFTR inhibitor moieties sepa-Chemistry & Biology 15rated by a sufficiently long spacer might be substantially more
potent in blocking CFTR than prior monovalent compounds. As
shown in Figure 1B, the divalent (MalH-PEG-MalH) and the
monovalent (MalH-PEG) conjugates were synthesized by reac-
tion of the corresponding bisamino and monoamino PEGs with
a 5-fold molar excess of MalH-DIDS in anhydrous DMSO in the
presence of triethylamine as a base catalyst. Unreacted MalH-
DIDS was removed by an amino-functionalized scavenger, and
the PEG conjugates were purified by controlled precipitation
and combinations of gel filtration, dialysis, ion exchange chro-
matography, and preparative HPLC.
Compound purity and absence of unreacted MalH-DIDS were
confirmed by HPLC/MS, and the PEG conjugates were charac-
terized by 1H NMR, mass spectrometry, and UV/visible spec-
troscopy. Figure 2A provides a representative 1H NMR spectrum
of 20 kDa MalH-PEG-MalH, showing a prominent peak for the
PEG protons and a relatively small peak in the aromatic region
seen after y-scale expansion. Similar NMR spectra were ob-
tained for the other conjugates. Mass spectra of monovalent
MalH-PEG conjugates of 0.75 and 2 kDa, and a divalent MalH-
PEG-MalH conjugate of 3 kDa, are provided in Figures 2B and
2C. Mass spectra confirmed the predicted molecular weights., 718–728, July 21, 2008 ª2008 Elsevier Ltd All rights reserved 719
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polydispersity, with the expected characteristic peak spacing
of CH2-CH2-O = 44 Da/charge.
Bisamino-PEGs of up to 20 kDa were available commercially,
giving solution lengths of up to 10 nm (Baird et al., 2003), slightly
less than that estimated for the distance between CFTR pores in
a potential CFTR dimer (Rosenberg et al., 2004; Riordan, 2005;
Guggino and Stanton, 2006), or in tightly packed CFTR clusters.
To generate larger conjugates with greater solution lengths to
potentially span inhibitor binding sites in CFTR clusters, available
PEGs of 40 and 108 kDa with terminal hydroxyls were converted
to mesylates, followed by reaction with sodium azide and Stau-
dinger reduction (Staudinger and Meyer 1919; Pal et al., 2004;
Figure 1C). The bisamino-PEGs were confirmed by 1H NMR, giv-
ing multiple peaks for CH2-NH2 in the range of 2.90–3.10 ppm,
and 13C NMR showing C-NH2 at 40 ppm (rather than
60 ppm for C-OH; spectra not shown).
Figure 2. Characterization of MalH-PEG
and MalH-PEG-MalH Conjugates
(A) 1H-NMR spectrum of 20 kDa diavalent MalH-
PEG-MalH conjugate showing peaks correspond-
ing to aliphatic and aromatic protons of PEG and
MalH moieties, respectively.
(B) Negative ion electrospray ionization (ESI) mass
spectra of monovalent MalH-PEG conjugates of
0.75 and 2 kDa.
(C) Negative ion ESI mass spectra for 3 kDa diva-
lent MalH-PEG-MalH conjugate showing the
peaks for [M]3 and [M]4 ions with polydispersity.
Improved CFTR Inhibition
of Divalent MalH-PEG-MalH
Conjugates
CFTR inhibition by the MalH-PEG conju-
gates was measured by a fluorescence
cell-based assay utilizing transfected
cells expressing human wild-type CFTR
and a yellow fluorescent protein (YFP) io-
dide sensor, as previously described (Ga-
lietta et al., 2001). CFTR-facilitated iodide
influx following extracellular iodide addi-
tion results in quenching of cytoplasmic
YFP fluorescence. Inhibitors were added
5 min after maximal stimulation of CFTR
with a mixture of forskolin, IBMX, and api-
genin. Figure 3A shows representative
original fluorescence data for conjugates
of 20 kDa molecular size showing sub-
stantially greater inhibition potency by
the divalent (left panel) versus monova-
lent (right panel) conjugate. Figure 3B
shows percentage CFTR inhibition, as
determined from initial curve slopes, for
each of the monovalent and divalent
conjugates. Figure 3C summarizes IC50
values and Hill coefficients determined
by nonlinear regression to a single-site
inhibition model. Remarkably lower IC50
values were found for all divalent versus monovalent conjugates,
with greater Hill coefficients, providing evidence for a coopera-
tive mechanism for CFTR inhibition by the divalent conjugates
in which both MalH moieties in a divalent conjugate interact
with CFTR.
Short-circuit current measurements were done to verify the
apical membrane surface site of action and relative potencies
of the MalH-PEG conjugates, and to determine the kinetics of
CFTR inhibition. Figures 4A and 4B show representative short-
circuit current data for inhibition of CFTR-mediated apical
membrane chloride current by the divalent and monovalent
MalH-PEGs, respectively. The conjugates were added only
to the solution bathing the apical cell surface. In general, inhi-
bition was rapid and was near complete at higher concentra-
tions of the conjugates. CFTR chloride current was inhibited
with IC50 values of <1 mM for many of the divalent conjugates,
whereas IC50 values for the monovalent conjugates were720 Chemistry & Biology 15, 718–728, July 21, 2008 ª2008 Elsevier Ltd All rights reserved
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agreement with those obtained by the fluorescence assay, al-
though exact values differ because of differences in assay
conditions, such as differences in apical membrane potential
and dilution effects in the fluorescence assay. In both assays,
IC50 values of the divalent compounds decreased with in-
creasing molecular size, except for the largest compound
(100 kDa). The size-dependent inhibition potency is likely the
consequence of several factors, including inhibitor steric ac-
cess to its binding site, the energetics and location of the
MalH binding site(s), and the conformational entropy of the
PEGs.
Figure 3. CFTR Inhibition by MalH-PEG
Conjugates
(A) Original fluorescence assay data for CFTR inhi-
bition by 20 kDa MalH-PEG-MalH (left) and MalH-
PEG (right). CFTR was maximally stimulated by
a mixture of forskolin, IBMX and apigenin in stably
transfected FRT cells coexpressing human CFTR
and the yellow fluorescent protein YFP-H148Q/
I152L. The fluorescence decrease following iodide
addition represents CFTR halide conductance.
(B) Concentration-inhibition data for indicated
monovalent and divalent conjugates determined
from the fluorescence assay. Error bars represent
± SE (n = 3–5). Data fitted to single-site inhibition
model.
(C) Fitted IC50 values for monovalent and divalent
conjugates as a function of molecular size, with cal-
culated gyration radii shown (left); fitted Hill coeffi-
cients (right). At each molecular size, IC50 values
and Hill coefficients differed significantly (p <
0.01; Student’s t test). Error bars represent ± SE.
Mechanism of CFTR Inhibition
by MalH-PEG Conjugates
Whole-cell patch-clamp was done to in-
vestigate the mechanism of CFTR inhibi-
tion by the MalH-PEG conjugates. Exper-
iments were done comparing monovalent
versus divalent conjugates of 20 kDa mo-
lecular size, where IC50 differed by >20-
fold. Whole-cell CFTR chloride currents
were measured in the absence of inhibi-
tors, and at concentrations near the IC50
values of 0.6 and 15 mM for the divalent
and monovalent conjugates, respectively.
Figures 5A and 5B show representative
traces, with averaged current-voltage re-
lationships shown in Figures 5C and 5D.
Both compounds produced voltage-de-
pendent inhibition of CFTR currents, with
positive currents being more strongly af-
fected, producing inwardly rectifying be-
havior, which is consistent with occlusion
of the channel pore. CFTR inhibition by
the MalH-PEG conjugates was reversible
following inhibitor washout, with recovery
to baseline current in 2–4 min.
The CFTR current traces at different membrane potentials re-
vealed slow channel block by the MalH-PEG conjugates. When
membrane voltage was clamped from a holding potential of
0 mV to a positive or a negative potential, CFTR currents
showed time-dependent decreases and increases, respectively
(Figure 5E). The kinetics fitted well to single exponential func-
tions with time constants in the range 100–200 ms, substantially
greater than those for GlyH-101 (8–10 ms) (Muanprasat et al.,
2004), although comparable to those of MalH-lectin conjugates
(Sonawane et al., 2007). The time constants showed little volt-
age dependence, and, at some potentials, were significantly
greater for the monovalent versus the divalent conjugatesChemistry & Biology 15, 718–728, July 21, 2008 ª2008 Elsevier Ltd All rights reserved 721
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CFTR Inhibitors for Cholera TherapyFigure 4. Short-Circuit Current Measurements of CFTR Inhibition
CFTR-mediated apical membrane chloride current measured in FRT cells expressing human wild-type CFTR after permeabilization of the basolateral membrane
in the presence of a chloride gradient (see Experimental Procedures). CFTR was activated by 20 mM forskolin, and indicated concentrations of divalent MalH-
PEG-MalH (A) and monovalent MalH-PEG (B) conjugates were added to apical bathing solution. (C) Deduced IC50 values. Error bars represent ± SE (n = 3–5).(Figure 5F). As further evidence that the MalH-PEG conjugates
act by a pore occlusion mechanism, lowering extracellular Cl
to 20 mM strongly reduced the block by MalH-PEG-MalH
(Figure 5G).
We estimated the distance of the MalH binding site along the
electric field with the Woodhull equation (Woodhull, 1973). As-
suming a valence (z) value of 1 for both monovalent and diva-
lent compounds, the computed fraction of the membrane poten-
tial sensed at the binding site relative to the extracellular surface
(d) is 0.21 and 0.33, respectively. If z is 2 for the divalent com-
pound, d becomes 0.17.
Outside-out patch-clamp measurements were carried out to
further investigate the mechanism of CFTR inhibition by the
MalH-PEG conjugates. To activate CFTR, the pipette (intracellu-
lar) solution contained 1 mM ATP and 5 mg/ml protein kinase A
catalytic subunit. Figures 6A and 6B show representative record-
ings of CFTR channel activity obtained at 60 mV in the absence
and presence of divalent and monovalent conjugates. Com-
pound addition to the extracellular side greatly reduced the du-
ration of channel openings. Data from multiple experiments are
summarized in Figures 6C and 6D. The MalH-PEG conjugates
significantly reduced apparent mean open time and open chan-
nel probability. Apparent mean closed time was significantly re-
duced by the monovalent MalH-PEG. This effect is probably due
to an increased number of brief intraburst closures, although the
prevalence of multichannel patches in our experiments pre-
cluded a more detailed analysis of possible multicomponent
channel closures in the presence of inhibitors. We also observed
a small (10%) but significant decrease in single-channel ampli-
tude (i). These results support the conclusion that MalH-PEG
conjugates inhibit CFTR by an external pore occlusion mecha-
nism (see Discussion).722 Chemistry & Biology 15, 718–728, July 21, 2008 ª2008 ElsevierDivalent MalH-PEG-MalH Conjugates Inhibit Cholera
Toxin-Induced Intestinal Fluid Secretion
Inhibition efficacy of divalent conjugates was investigated in T84
colonic epithelial cells under nonpermeabilized conditions and in
the absence of a Cl gradient. CFTR was activated by forskolin,
and then MalH-PEG conjugates were added to the chamber
bathing the apical cell surface. Figure 7A shows inhibition of for-
skolin-stimulated short-circuit current by 20 and 40 kDa MalH-
PEG-MalH in T84 cells with IC50 values 1 mM.
The divalent MalH-PEG-MalH conjugates were tested for their
antisecretory efficacy in mice in both intestinal closed-loop and
suckling mouse survival models. Midjejunal loops were injected
with either saline or cholera toxin containing different concentra-
tions of test compounds, and intestinal fluid secretion was mea-
sured at 6 hr. Figure 7B shows a loop weight-to-length ratio of
0.06 g/cm in PBS-injected loops (corresponding to 100% inhibi-
tion), and 0.22 g/cm for cholera toxin-injected loops (corre-
sponding to 0% inhibition). The divalent MalH-CFTR conjugates
of 2, 10, 20, and 40 kDa molecular sizes inhibited cholera toxin-
induced fluid secretion in a concentration-dependent manner,
with IC50 values of 100, 10, 10, and 100 pmol/loop, respec-
tively. PEG alone (bar at right) did not inhibit intestinal fluid accu-
mulation.
Figure 7C summarizes the suckling mouse survival studies.
Suckling 3–4 day-old Balb-C mice receiving a single oral dose
of cholera toxin generally died by 20 hr, with no mortality in vehi-
cle control (saline gavaged) mice over >24 hr. Survival of mice
receiving cholera toxin was significantly improved when the
divalent conjugate was gavaged along with cholera toxin.
However, the survival of the inhibitor-treated mice was not
100%, which may have resulted from several factors, including
imperfect inhibitor retention, intestinal distribution, and CFTRLtd All rights reserved
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CFTR Inhibitors for Cholera TherapyFigure 5. Electrophysiological Analysis of CFTR Inhibition by 20 kDa Conjugates
(A and B) Representative whole-cell membrane currents from CFTR-expressing FRT cells. Each panel shows superimposed membrane currents induced at dif-
ferent membrane potentials (from 100 to +100 mV) in 20 mV steps of 600 ms duration. Each pulse was followed by a 600 ms step at 100 mV. The interpulse
interval was 4 s. Currents were measured before (upper panels), during (middle panels), and after (lower panels) application of the conjugates (0.6 mM for MalH-
PEG-MalH; 15 mM for MalH-PEG). Forskolin (5 mM) was present throughout all meaurements.
(C and D) Current-voltage relationships from whole-cell experiments as in (A) and (B). The current amplitude was reported as an average value at the end (550–600 ms)
of the pulse, normalized to cell capacitance. Each point is the average. Error bars represent ± SE (four to five experiments). The inhibitors significantly reduced
(p < 0.05) membrane current at voltages between 60 and 100 mV for MalH-PEG-MalH, and at all voltages, except 0 mV, for MalH-PEG.
(E) Kinetics of current relaxations elicited at indicated membrane voltages. Single exponential regressions are shown.
(F) Time constants measured at the indicated membrane voltages (Vm) by single exponential regression of current relaxations. Error bars represent ± SE (four to
five experiments; *p < 0.05). Concentrations were 0.6 mM for MalH-PEG-MalH and 15 mM for MalH-PEG.
(G) Effect of extracellular Cl concentration on MalH-PEG-MalH block. Inhibition of CFTR current measured at 60 mV in the presence of 154 or 20 mM extracel-
lular Cl. Symbols are the mean of three to five different experiments. Error bars represent ± SE (*p < 0.05).inhibition, as well as cholera toxin-related inhibition of intestinal
fluid absorption.
DISCUSSION
Our study builds on a body of data on the discovery, external
pore occlusion mechanism, and structure-activity relationship
analysis of GlyH-type CFTR inhibitors, and their efficacy in block-
ing enterotoxin-mediated intestinal fluid secretion. The goal here
was to develop nonabsorbable, potent CFTR inhibitors, which,
unlike lectin conjugates (Sonawane et al., 2007), would be inex-Chemistry & Biology 15pensive, chemically stable, and nonimmunogenic. PEGs have
been used extensively (at high concentrations) as laxatives in hu-
mans, and have an excellent safety profile (Migeon-Duballet
et al., 2006). We found that conjugation of MalH CFTR-blocking
moieties to a PEG backbone renders the MalH-PEG conjugate
membrane impermeant and nonabsorbable, yet allows MalH ac-
cess to its CFTR-blocking site at the extracellular surface of the
CFTR anion pore. To improve the potency of prior GlyH analogs
and conjugates, which had IC50 values of 5 mM or greater (Muan-
prasat et al., 2004), we tested a series of multivalent CFTR
blocker conjugates to PEGs, dextrans, dendrimers, and various, 718–728, July 21, 2008 ª2008 Elsevier Ltd All rights reserved 723
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PEGs, containing MalH CFTR-blocking moieties at their termini,
generally had >20-fold-improved potency for CFTR inhibition
over monovalent conjugates, and had the requisite properties
mentioned above for antidiarrheal applications. The greatly en-
hanced potency of divalent versus monovalent MalH-PEGs,
and the relatively poor efficacy of the various other conjugates,
could not be predicted in advance.
Experiments were done to investigate the mechanism of the
greatly improved potency of divalent versus monovalent MalH-
PEGs. The 2-fold-greater Hill coefficient for CFTR inhibition
by divalent versus monovalent conjugates suggested coopera-
tivity in binding as a key element in their improved potency,
which could result from simultaneous two-site binding, or to var-
ious diffusion-concentration mechanisms whereby multivalency
results in increased local concentration (Gestwicki et al., 2002).
Simultaneous two-site binding would predict strongly size-de-
pendent potency (Kramer and Karpen, 1998), in which the po-
tency would be abruptly and strongly increased as the inter-
MalH spacing exceeds the distance between binding sites on
two CFTR monomers. This was not the case. The substantially
greater potency of divalent versus monovalent MalH-PEGs for
all size PEGs, even for very small PEGs of <200 Da (predicted so-
lution length, 0.97 nm), excludes this possibility, as the pore-
pore separation between CFTR monomers is unlikely to be
less than 11 nm (Rosenberg et al., 2004; Riordan, 2005; Gug-
gino and Stanton, 2006). Our data thus suggest that the relatively
high CFTR inhibition potency of the divalent MalH-PEGs is a con-
sequence of the increased concentration at the external CFTR
pore afforded by one-site/two-ligand binding.
Patch-clamp analysis indicated that the MalH-PEGs block
CFTR chloride channel function in a voltage-dependent manner,
similar to that found for unconjugated GlyH-101. In whole-cell
patch-clamp recordings, inhibition by the divalent and monova-
lent conjugates was increased and reduced at positive and
negative membrane potentials, respectively, and modulated by
extracellular Cl concentration. This behavior supports the
Figure 6. Outside-Out Patch-Clamp Recordings of CFTR Inhibition
by MalH-PEG Conjugates
(A and B) Representative traces recorded at 60 mV showing CFTR single chan-
nel activity in the absence and presence of 20 kDa divalent and monovalent
conjugates (2 and 15 mM, respectively). Pipette (intracellular) solution con-
tained 1 mM ATP and 5 mg/ml protein kinase A catalytic subunit. Channel
openings shown as upward deflections from the closed channel level (lowest
currents).
(C and D) Summary of single-channel analysis for divalent and monovalent
20 kDa MalH-PEGs. Error bars represent 1 SE (four experiments; *p < 0.05;
**p < 0.01).
Figure 7. Antidiarrheal Efficacy of Divalent MalH-PEG-MalH
Conjugates
(A) Inhibition of CFTR stimulated short-circuit current in human intestinal T84
cells (nonpermeabilized) by 20 and 40 kDa MalH-PEG-MalH. Data are repre-
sentative of three sets of experiments. Where indicated, forskolin (20 mM)
was added to activate CFTR. Baseline current was 3–7 mA.
(B) Intestinal fluid accumulation at 6 h, quantified by intestinal loop weight-to-
length ratio, in closed midjejunal loops in mice. Error bars represent 1 SE (six to
eight loops studied per condition; *p < 0.05, ANOVA).
(C) Improved survival of suckling mice (32 mice per group) following gavage
with cholera toxin without versus with 200 pmol of 20 kDa MalH-PEG-MalH
(p = 0.026, log-rank test). In vehicle control, mice were identically processed,
but did not receive cholera toxin or inhibitors.724 Chemistry & Biology 15, 718–728, July 21, 2008 ª2008 Elsevier Ltd All rights reserved
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the CFTR pore from the extracellular side, and interacts at
a site within the pore in which the blocker is sensitive to trans-
membrane electrical potential. Through the use of the Woodhull
equation, the MalH-PEG conjugates appear to bind to a relatively
shallow site (d = 0.2–0.3), in agreement with CFTR pore models
that postulate an asymmetric organization, with a deep and
wide intracellular vestibule and a shorter extracellular access
(Hwang and Sheppard, 1999; McCarty, 2000). Other CFTR
blockers, including glibenclamide and disulfonic stilbenes, bind
to the intracellular site of the pore and sense a higher fraction
of transmembrane electrical field (d = 0.4–0.5) (McCarty et al.,
1993; Linsdell and Hanrahan, 1996; Sheppard and Robinson,
1997). We calculated d for MalH-PEG-MalH for a z of 1 or
2, although we think that 1 is more appropriate. Although
MalH-PEG-MalH has a net charge of2, the two charges are lo-
cated on opposite ends of PEG molecule, so that it is unlikely that
both charges enter the same pore unless the molecule is tightly
coiled and the charges are close to each other.
Outside-out patch-clamp recordings confirmed an external
pore occlusion mechanism for CFTR inhibition by the MalH-
PEG conjugates. The MalH-PEG conjugates affected primarily
the channel open state, decreasing apparent mean open time.
The time course of channel block and unblock in response to
changes in membrane voltage, as measured in whole-cell re-
cordings, showed single exponential behavior. A more complex
mechanism, involving multiple steps with different time con-
stants, would have produced multicomponent kinetics. The sin-
gle time constants describing the kinetics of channel block and
unblock were much greater than those of unconjugated GlyH-
101, but comparable to those of the lectin conjugates. Also, in
contrast to steady-state currents, the kinetics of block and un-
block showed little voltage dependence, suggesting a high-en-
ergy, rate-limiting barrier that slows blocker entry and exit.
From these findings, we postulate that conjugation reduces the
mobility of the MalH pore-blocking moiety because of frictional
interactions of the PEG chain within CFTR channel walls. Previ-
ous studies have evidenced the importance of such interactions
in the mobility of linear macromolecules crossing transmem-
brane channels (Mathe et al., 2005).
Two mouse models of cholera were used to test the antisecre-
tory properties of the divalent MalH-PEGs. The closed-loop
model quantifies the accumulation of fluid in midjejunal loops
in response to cholera toxin. This is a well-established and tech-
nically simple quantitative model in which fluid secretion and ab-
sorption mechanisms are intact, although there is no intestinal
transit (Oi et al., 2002). Unfortunately, other than primates and
surgically manipulated rabbits, suitable animal models of hu-
man-like secretory diarrheas are not available. As used here,
the suckling mouse model, in which survival is the endpoint for
intestinal fluid loss, is a reasonable model of cholera, although
it does not accurately recapitulate human intestinal size, transit
times, and fluid absorption/secretion rates (Takeda et al., 1978;
Sonawane et al., 2007). Notwithstanding these caveats, the anti-
secretory potency of the divalent conjugates provides proof of
concept for their antidiarrheal efficacy in vivo.
In summary, we have synthesized and characterized nonab-
sorbable, divalent MalH-PEG conjugates with nanomolar CFTR
inhibition potency, which are effective in blocking choleraChemistry & Biology 15toxin-induced intestinal fluid secretion in mouse models of chol-
era. The safety, high potency, low cost, and chemical stability of
these conjugates offer advantages over existing pore-blocking
CFTR inhibitors, making them potential lead candidates for fur-
ther preclinical development.
SIGNIFICANCE
Secretory diarrheas, such as cholera and traveler’s diarrhea,
are major health problems in developing countries. The cur-
rent therapy—oral replacement of fluid losses—is primarily
supportive. Oral replacement therapy has limited efficacy
in the very young and old, andwhen cleanwater and ‘‘oral re-
hydration salt’’ mixture is not available. Therapy directed at
reducing intestinal fluid secretion (antisecretory therapy)
has the potential to overcome limitations of existing thera-
pies. The cystic fibrosis chloride channel (CFTR) is the
main pathway involved in fluid secretion in secretory diar-
rheas. Because CFTR is expressed at the luminal membrane
of intestinal epithelial cells (enterocytes), it represents
a unique target for development of an orally administered,
nonabsorbable CFTR inhibitor. We report the development
of such an inhibitor, which involved conjugation of a CFTR
pore-blocking moiety (MalH) with a polyethylene glycol
(PEG) macromolecular backbone. PEGs are safe and render
the CFTR inhibitor nonabsorbable. We discovered greatly
enhanced potency by linking two MalH moieties to opposite
ends of one PEG. The macromolecular CFTR inhibitors are
shown by patch-clamp analysis to block CFTR by an exter-
nal pore occlusion mechanism, and are found to effectively
block intestinal fluid secretion in mouse models of cholera.
Because of their high potency, chemical stability, and mem-
brane impermeability, the MalH-PEG conjugates developed
in this study have potential application as safe oral antise-
cretory therapy in cholera and traveler’s diarrhea.
EXPERIMENTAL PROCEDURES
Synthesis Procedures
1H and 13C NMR spectra were obtained in CDCl3 or DMSO-d6 with a 400 MHz
Varian Spectrometer referenced to CDCl3 or DMSO. Mass spectrometry was
performed on a Waters LC/MS system (Alliance HT 2790+ZQ, HPLC; model
2690; Waters, Milford, MA). Flash chromatography was performed with EM sil-
ica gel (230–400 mesh), and thin-layer chromatography was performed on
Merk silica gel 60 F254 plates.
MalH-PEG-MalH and MalH-PEG, General Procedure
Bisamino or mono-amino PEGs (0.25, 1, 2, 3, 6, 10, 20 kDa; Sigma; 40 and
100 kDa synthesized as described below) (each 20 mg in 0.5 ml DMSO),
MalH-DIDS (5 molar excess; Sonawane et al., 2007), and triethylamine
(5-fold molar excess) were stirred slowly at room temperature for 1 hr.
Amino-functionalized silica gel (10-fold molar excess) was added and stirred
for an additional 2 hr. The reaction mixture was filtered, scavenger was washed
with 1 ml DMSO, and the combined filtrate was added dropwise with stirring
into 50 ml methanol. The precipitated product was filtered and washed twice
with methanol. PEG conjugates of 6 kDa size and lower were further purified by
anion exchange chromatography (sepharose; GE) with NaCl gradient (0.5–
1.0 M) elution. PEG conjugates of 10, 20, 40, and 100 kDa sizes were dialyzed
by overnight dialysis against PBS. Larger PEG conjugates were purified by gel
filtration (sephadex G25).
MalH-PEG0.1kDa-OH: yield, 49%; mp > 300C; 1H NMR (D2O): d 3.194.44
(s, 8H, PEG-CH2), 4.72, 5.22 (d, m,1H, COCH), 7.60–7.88 (m, Ar-H), MS (ES), 718–728, July 21, 2008 ª2008 Elsevier Ltd All rights reserved 725
Chemistry & Biology
CFTR Inhibitors for Cholera Therapy(m/z): [M-2H]2 and [M-1] calculated for C40H38Br2N8O11S4, 546.43 and
1094.86, found 545, 546, 547 [M-2H]2, 1091, 1093, 1095 [M-H].
MalH-PEG0.75kDa-OMe: yield, 18%; 1H NMR (D2O): d, 2.85 (s, OCH3), 3.52
(s, PEG-CH2), 7.60–7.82 (m, Ar-H), MS (ES
+) (m/z): ([M]2-+Na+)/2 calculated for
C69H96Br2N8O25S4, 896.31, found 896 ± 22, 44, 88, 176 (Figure 2B).
MalH-PEG2kDa-OMe: yield 31%; 1H NMR (D2O): d, 2.69 (s, O-CH3), 3.21
(s, PEG-CH2), 7.57–7.90 (m, Ar-H), MS (ES
+) (m/z): [M-2H]2- calculated for
C121H200Br2N8O51S4, 1433.0, found 1432.8 ± 22, 44, 88, 176 (Figure 2B).
MalH-PEG5kDa-OMe: yield 53%; 1H NMR (D2O): d, 2.64 (s, O-CH3), 3.50
(s, PEG-CH2), 7.38–7.91 (m, Ar-H); Conjugation ratio, MalH:PEG 1: 1.04 (UV/
Visible).
MalH-PEG10kDa-OMe: yield 62%; 1H NMR (D2O): d, 2.58 (s, O-CH3), 3.49 (s,
PEG-CH2), 7.55–8.07 (m, Ar-H); Conjugation ratio, MalH:PEG 1: 1.08 (UV/
Visible).
MalH-PEG20kDa-OMe: yield 39%; 1H NMR (D2O): d, 2.59 (s, O-CH3), 3.48
(s, PEG-CH2), 7.40–7.96 (m, Ar-H); Conjugation ratio, MalH:PEG 1: 0.96 (UV/
Visible).
MalH-PEG0.14kDa-MalH: yield 29%; 1H NMR (D2O): d, 3.21–3.60 (m, PEG-
CH2), 3.62–3.71 (m, PEG-CH2), 7.27–7.82 (m, Ar-H), MS (ES
+) (m/z): [M-2H]2
and ([M-2H]2 3Na+) calculated for C78H70Br4N16O20S8, 1062.82 and 1131.82,
found 1062.94 and 1130.88.
MalH-PEG3kDa-MalH: yield 44%; 1H NMR (D2O): d, 3.48 (s, PEG-CH2),
7.13–780 (m, Ar-H), MS (ES+) (m/z): [[M-4H]4-+ Na+]/4 calculated for
C224H362Br4N16O93S8, 1339.25, found 1339 (Figure 2B).
MalH-PEG6kDa-MalH: yield 26%; 1H NMR (D2O): d, 3.51 (s, PEG-CH2),
7.22–8.14 (m, Ar-H); conjugation ratio, MalH:PEG 2: 1.11 (UV/Visible).
MalH-PEG10kDa-MalH: yield 23%; 1H NMR (D2O): d, 3.46 (s, PEG-CH2),
7.05–8.21 (m, Ar-H); conjugation ratio, MalH:PEG 2: 0.92 (UV/Visible).
MalH-PEG20kDa-MalH: yield 55%; 1H NMR (D2O): d, 3.53 (s, PEG-CH2),
7.14–7.91 (m, Ar-H); conjugation ratio, MalH:PEG 2: 1.07 (UV/Visible).
MalH-PEG40kDa-MalH: yield 27%; 1H NMR (D2O): d, 3.53 (s, PEG-CH2),
7.13–8.12 (m, Ar-H); conjugation ratio, MalH:PEG 2: 0.95 (UV/Visible).
MalH-PEG108kDa-MalH: yield 58%; 1H NMR (D2O): d, 3.60 (s, PEG-CH2),
7.07–7.89 (m, Ar-H); conjugation ratio, MalH:PEG 2: 1.08 (UV/Visible).
Bisamino-PEGs, 40 and 100 kDa
To a mixture of PEG (25 mmol, 40 and 108 kDa; Sigma) and triethylamine (14 ml,
100 mmol) in 2–5 ml CH2Cl2, methane sulfonyl chloride (52 mmol) was added
dropwise at 0C and stirred for 6 hr at room temperature. The reaction mixture
was washed with sodium bicarbonate (50 mM, 2 ml) and the organic phase
was dried (MgSO4). The evaporated organic phase yielded 1,w-dimethanesul-
fonylpolyoxyethylenes of 40 and 100 kDa, which were dissolved in 2 ml DMSO,
and NaN3 (13 mg, 0.2 mmol) was added and stirred for 6 hr at 50
C. After cool-
ing, water (20 ml) was added, and the PEG-azide was extracted in dichlorome-
thane and evaporated. A mixture of the PEG-azide (10 mmol) and triphenyl-
phosphine (8 mg, 30 mmol) in dry methanol (3 ml) was refluxed for 1 hr and
solvent was removed under reduced pressure. The residue was dissolved in
dichloromethane (10 ml), filtered, and then exposed to dry hydrogen chloride
gas. The precipitated hydrochloride salt of bisamino PEG was filtered. The so-
lution was cooled at 4C overnight, and the precipitated hydrogen chloride salt
was further purified by cation exchange chromatography with carboxymethyl
CM-sephadex C25, eluted with 10 mM Tris, pH 9.0, and a 2 L gradient of 0.1–
2.0 M NaCl. H2N-PEG 40 kDa-NH2: 26% yield,
1H NMR (D2O): d, 2.91 (m, -CH2-
N), 3.27 (t, O-CH2-C-N), 3.52 (s, PEG-CH2). H2N-PEG108kDa-NH2: 38% yield,
1H NMR (D2O): d, 2.90 (m, -CH2-N), 3.31 (t, O-CH2-C-N), 3.51 (s, PEG-CH2).
Fluorescence Cell-Based Assay of CFTR Inhibition
Fisher rat thyroid (FRT) cells stably expressing wild-type human CFTR and
YFP-H148Q were cultured on 96 well black-wall plates, as previously de-
scribed (Ma et al., 2002). Cells in 96 well plates were washed three times,
and then CFTR was activated by incubation for 15 min with an activating cock-
tail containing 10 mM forskolin, 20 mM apigenin, and 100 mM IBMX. Test com-
pounds were added 5 min before assay of iodide influx in which cells were ex-
posed to a 100 mM inwardly directed iodide gradient. YFP fluorescence was
recorded for 2 s before and 12 s after creation of the iodide gradient. Initial
rates of iodide influx were computed from the time course of decreasing fluo-
rescence after the iodide gradient.726 Chemistry & Biology 15, 718–728, July 21, 2008 ª2008 ElsevierShort-Circuit Current Measurements
FRT cells (stably expressing human wild-type CFTR) were cultured on
Snapwell filters with 1 cm2 surface area (Corning-Costar) to resistance of
>1,000 U $ cm2, as previously described (Sonawane et al., 2007). Filters were
mounted in an Easymount Chamber System (Physiologic Instruments, San
Diego, CA). For apical Cl current measurements, the basolateral hemicham-
ber contained: 130 mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 1 mM CaCl2,
0.5 mM MgCl2, 10 mM Na-HEPES, 10 mM glucose (pH 7.3). The basolateral
membrane was permeabilized with amphotericin B (250 mg/ml) for 30 min. In
the apical solution 65 mM NaCl was replaced by sodium gluconate, and
CaCl2 was increased to 2 mM to compensate for Ca
2+ buffering by gluconate.
The basolateral-to-apical Cl gradient induces upward current deflections,
indicating flow of Cl from the basolateral to the apical side of the epithelium.
Solutions were bubbled with 95% O2/5% CO2 and maintained at 37
C. Current
was recorded with a DVC-1000 voltage clamp (World Precision Instruments)
with Ag/AgCl electrodes and 1 M KCl agar bridges.
Closed Intestinal Loop Model of Cholera
Mice (CD1 strain, 28–34 g) were given 5% sucrose for 24 hr prior to anesthesia
(2.5% avertin intraperitoneally). Body temperature was maintained at 36C–
38C with a heating pad. Following a small abdominal incision, three or four
closed midjejunal loops (length, 15–20 mm) were isolated by sutures. Loops
were injected with 100 ml PBS or PBS containing cholera toxin (1 mg), without
or with test compounds. The abdominal incision was closed with sutures, and
the mice were allowed to recover from anesthesia. At 6 hr, the mice were again
anesthetized, the intestinal loops were removed, and loop length and weight
were measured to quantify net fluid accumulation. Mice were killed by an
overdose of avertin. All protocols were approved by the UCSF Committee
on Animal Research.
Suckling Mouse Model of Cholera
Equal numbers of newborn Balb-C mice from the same mother(s), each weigh-
ing 2–3 g (age 3–4 days), were gavaged with PE-10 tubing with 10 mg cholera
toxin in a 50 ml volume containing 50 mM Tris, 200 mM NaCl, and 0.08% Evans
blue (pH 7.5), with or without MalH-PEG 20 kDa-MalH (5 nmol). Control mice
were gavaged with buffer alone. Successful gavage was confirmed by Evans
blue localization in stomach/intestine. Mouse survival was assessed hourly.
Patch-Clamp Analysis
Patch-clamp experiments were carried out at room temperature on FRT cells
stably expressing wild-type CFTR. Whole-cell and outside-out configurations
were used. For whole-cell experiments, the pipette solution contained:
120 mM CsCl, 10 mM TEA-Cl, 0.5 mM EGTA, 1 mM MgCl2, 40 mM mannitol,
10 mM Cs-HEPES, and 1 mM MgATP (pH 7.3). For outside-out patches, the
pipette solution contained: 150 mM NMDG-Cl, 2 mM MgCl2, 10 mM EGTA,
10 mM HEPES, 1 mM ATP (pH 7.3). This pipette solution was supplemented
with 125 nM catalytic subunit of protein kinase A (Promega). The stock solution
of the catalytic subunit of protein kinase A was further diluted up to 250 mg/ml
in a buffer containing dithiothreitol and aliquots were kept at80C. After thaw-
ing, aliquots were maintained at 4C for not more than 2 weeks. The bath solu-
tion in all experiments was: 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, 10 mM
glucose, 10 mM mannitol, 10 mM Na-HEPES (pH 7.4). The cell membrane
was clamped at specified voltages with an EPC-7 patch-clamp amplifier (List
Medical). Data were filtered at 500 Hz (whole cell) or 200 Hz (outside-out), and
digitized at 1,000 Hz with an Instrutech ITC-16 AD/DA interface and PULSE soft-
ware (Heka). Mean cell capacitance was 17.8 ± 1.6 pF (n = 19). Inhibitors were
applied by extracellular perfusion. Whole-cell and single-channel recordings
were analyzed with IgorPro software (Wavemetrics) and custom procedures.
In the outside-out configuration, most membrane patches contained several
channels (three to nine), precluding dwell time analysis and determination of
dwell time constants for open and closed channel states. Therefore, blocker ef-
fects were described by mean open and closed times.
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